More recently, structural variants in the 3’untranslated region of the PD-L1 were described as a potential genetic marker of response to anti-PD1 checkpoint inhibitor therapy [59] These structural variants affected multiple cancer types, including adult T-cell leukemia/lymphoma (27%), diffuse large B-cell lymphoma (8%), gastric adenocarcinoma (2%). Here, CD274 is linked to cancer.